Skip to main content
SpringerLink
Log in

Physical Characterization of 1,3-dipropyl-8-cyclopentylxanthine (CPX)

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

1,3-dipropyl-8-cyclopentylxanthine (CPX) has been shown to stimulate in vitro CFTR activity in ∆F508 cells. Data from a phase I study demonstrated erratic bioavailability and no measurable clinical response to oral CPX. One cause for its poor bioavailability may have been dissolution rate limited absorption, but there is little published physicochemical data on which to base an analysis. The objective of this study was to determine the solubility and solid-state characteristics of CPX. CPX is a weak acid with pKa of 9.83 and water solubility at pH 7.0 of 15.6 μM. Both laureth-23 and poloxamer 407 increased the apparent water solubility linearly with increasing concentrations. CPX exists in two crystal forms, one of which (form II) has been solved. Form II is a triclinic crystal with space group P1 and calculated density of 1.278 g/cm3. X-ray powder diffraction and differential scanning calorimetry studies (DSC) indicated that CPX crystals prepared at room temperature were mixtures of forms I and II. DSC results indicated a melting point of approximately 195°C for form I and 198°C for form II. Thermogravimetric analysis indicated no solvent loss upon heating. Dynamic water vapor sorption data indicated no significant water uptake by CPX up to 90% RH. Analysis of the data indicates that CPX may not be amenable to traditional formulation approaches for oral delivery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

REFERENCES

  1. Gadsby DC, Vergani P, Csanady L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature. 2006;440:477–83.

    Article  CAS  PubMed  Google Scholar 

  2. Strasbaugh SD, Davis PB. Cystic fibrosis: a review of epidemiology and pathobiology. Clin Chest Med. 2007;28:279–88.

    Article  Google Scholar 

  3. Registry P. Annual report. Bethesda, MD: Cystic Fibrosis Foundation; 2005. 2006.

    Google Scholar 

  4. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 1990;163:827–34.

    Article  Google Scholar 

  5. Andersson C, Roomans G. Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur Respir J. 2000;15:937–41.

    Article  CAS  PubMed  Google Scholar 

  6. Cohen B, Lee G, Jacobson K, Kim Y, Huang Z, Sorscher E et al. 8-cyclopentyl-1, 3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochem. 1997;36:6455–61.

    Article  CAS  Google Scholar 

  7. Eidelman O, Barnoy S, Razin M, Zhang J, Mcphie P, Lee G et al. Role for phospholipid interactions in the trafficking defect of Delta F508-CFTR. Biochem. 2002;41:11161–70.

    Article  CAS  Google Scholar 

  8. Eidelman O, Guay-Broder C, Van Galen PJM, Jacobson KA, Fox C, Turner RJ et al. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci USA. 1992;89:5562–6.

    Article  CAS  PubMed  Google Scholar 

  9. Jacobson KA, Guay-Broder C, Van Galen PJM, Gallo-Rodriguez C, Melman N, Jacobson MA et al. Stimulation by alkylxanthines of chloride efflux in CFPAC-1 cells does not involve A1 adenosine receptors. Biochem. 1995;34:9088–94.

    Article  CAS  Google Scholar 

  10. US FDA: Cumulative list of all orphan designated products. www.fda.gov/orphan/designat/alldes.rtf. Accessed 24 Aug 2007.

  11. Pollard HB, Van Galen PJM, Jacobson KA, inventors; United States of America as represented by the Department of Health and Human Service, assignee. Method of treating cystic fibrosis using 8-cyclopenty-1,3-dipropylxanthine or xanthine amino congeners. US patent 5,366,977. 1994 Nov 22.

  12. McCarty NA, Standaert TA, Teresi M, Tuthill C, Launspach J, Kelly TJ et al. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol. 2002;33:90–8.

    Article  PubMed  Google Scholar 

  13. SciFinder Scholar: Substance detail 102146-07-6. Accessed 19 Mar 2009.

  14. Daly J, Padgett W, Shamim M, Butts-Lamb P, Waters J. 1, 3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors. J Med Chem. 1985;28:487–92.

    Article  CAS  PubMed  Google Scholar 

  15. Erickson R, Hiner R, Feeney S, Blake P, Rzeszotarski W, Hicks R et al. 1, 3, 8-trisubstituted xanthines. Effects of substitution pattern upon adenosine receptor A1/A2 affinity. J Med Chem. 1991;34:1431–5.

    Article  CAS  PubMed  Google Scholar 

  16. Scammells P, Baker S, Belardinelli L, Olsson R. Substituted 1, 3-dipropylxanthines as irreversible antagonists of A1 adenosine receptors. J Med Chem. 1994;37:2704–12.

    Article  CAS  PubMed  Google Scholar 

  17. Shamim MT, Ukena D, Padgett W, Hong O, Daly J. 8-Aryl-and 8-cycloalkyl-1, 3-dipropylxanthines: further potent and selective antagonists for A1-adenosine receptors. J Med Chem. 1988;31:613–7.

    Article  CAS  PubMed  Google Scholar 

  18. Martin A. Physical pharmacy. 4th ed. Baltimore, MD: Williams & Wilkins; 1993.

    Google Scholar 

  19. Otwinowski Z, Minor W. Processing of x-ray diffraction data collected in oscillation mode. In: Carter Jr CW, Sweet RM, editors. Macromolecular crystallography, Part A. New York: Academic; 1997. p. 307–26.

    Chapter  Google Scholar 

  20. Sheldrick G. Shelxl97 and Shelxs97 [Computer Software]. Germany: University of Göttingen; 1997.

    Google Scholar 

  21. Sheldrick G. Shelxtl/PC [Computer Software]. Madison, WI: Siemens Analytical X-ray Instruments, Inc; 1995.

    Google Scholar 

  22. US FDA: Guidance for Industry: Waiver of in vivo bioavailabilty and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. http://www.dfa.gov/cder/guidance/index.htm Accessed 19 Mar 2009.

  23. Benet L, Amidon G, Barends D, Lennernas H, Polli J, Shah V et al. The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res. 2008;25:483–8.

    Article  CAS  PubMed  Google Scholar 

  24. Gu CH, Li H, Levons J, Lentz K, Gandhi R, Raghavan K et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res. 2007;24:1118–30.

    Article  CAS  PubMed  Google Scholar 

  25. Martinez M, Amidon G. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42:620–43.

    Article  CAS  PubMed  Google Scholar 

  26. Wu C, Benet L. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11–23.

    Article  CAS  PubMed  Google Scholar 

  27. Yu LX. An integrated model for determining causes of poor oral drug absorption. Pharm Res. 1999;16:1883–7.

    Article  CAS  PubMed  Google Scholar 

  28. Rudolph A, Tuthill C, inventors. Pharmaceutical formulations comprising substituted xanthine compounds. United States patent application 2006/0052404 A1.

  29. Technical data on Pluronic(R) polyols. BASF Corporation.

  30. Cohen J. Theophylline. Anal Profiles Drug Subst. 1975;4:466–93.

    CAS  Google Scholar 

  31. McPherson TB. Characterization of the aqueous solubility of CPX. AAPS Journal. 2006;8:T2278.

    Google Scholar 

  32. Stephenson G. Anisotropic lattice contraction in pharmaceuticals: the influence of cryo-crystallography on calculated powder diffraction patterns. J Pharm Sci. 2006;95:821–7.

    Article  CAS  PubMed  Google Scholar 

Download references

ACKNOWLEDGMENTS

The authors acknowledge SciClone Pharmaceuticals, Inc. for providing CPX for solubility experiments and Dr. A. Michael Crider for assistance with CPX synthesis. We acknowledge support via National Science Foundation grants DMR-0449633 (TL) and DUE-0410642 (SIUE).

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville School of Pharmacy, Edwardsville, Illinois, 62026, USA

    Timothy McPherson & William Kolling

  2. Exelixis Inc., South San Francisco, California, USA

    Rahul V. Manek

  3. Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA

    Sihui Long & Tonglei Li

Authors
  1. Timothy McPherson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rahul V. Manek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William Kolling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sihui Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tonglei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy McPherson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McPherson, T., Manek, R.V., Kolling, W. et al. Physical Characterization of 1,3-dipropyl-8-cyclopentylxanthine (CPX). AAPS PharmSciTech 11, 720–728 (2010). https://doi.org/10.1208/s12249-010-9436-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-010-9436-6

Key words

Search

Navigation